Australian Clinical Labs (ASX:ACL) - Prezzo delle azioni, notizie e analisi

ACL Panoramica delle azioni

Australian Clinical Labs Limited fornisce servizi di diagnostica patologica in Australia. Maggiori dettagli

ACL analisi fondamentale
Punteggio fiocco di neve
Valutazione	3/6
Crescita futura	3/6
Prestazioni passate	1/6
Salute finanziaria	4/6
Dividendi	2/6

Premi

Negoziato a 42.5% al di sotto della nostra stima del suo valore equo

Si prevede che gli utili cresceranno del 15.98% all'anno

Analisi del rischio

Grandi elementi una tantum che incidono sui risultati finanziari

Il dividendo di 3.51% non è ben coperto dagli utili

I margini di profitto (3.4%) sono inferiori rispetto allo scorso anno (5.2%)

Australian Clinical Labs Limited Concorrenti

Healthia

ASX:HLA

AU$252.1m

SILK Laser Australia

ASX:SLA

AU$177.4m

Apiam Animal Health

ASX:AHX

AU$85.8m

Sonic Healthcare

ASX:SHL

AU$13.4b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Australian Clinical Labs
Prezzi storici delle azioni
Prezzo attuale dell'azione	AU$3.42
Massimo di 52 settimane	AU$3.86
Minimo di 52 settimane	AU$2.14
Beta	1.15
1Variazione di 1 mese	-5.52%
Variazione a 3 mesi	22.14%
Variazione di 1 anno	34.12%
3Variazione a 3 anni	-18.76%
Variazione a 5 anni	n/a
Variazione dall'IPO	0%

Notizie e aggiornamenti recenti

Why Investors Shouldn't Be Surprised By Australian Clinical Labs Limited's (ASX:ACL) 29% Share Price Surge

Sep 03

Should You Think About Buying Australian Clinical Labs Limited (ASX:ACL) Now?

Sep 02

Recent updates

Why Investors Shouldn't Be Surprised By Australian Clinical Labs Limited's (ASX:ACL) 29% Share Price Surge

Sep 03

Here's Why We Think Australian Clinical Labs (ASX:ACL) Might Deserve Your Attention Today

Aug 14

Australian Clinical Labs Limited (ASX:ACL) Just Reported Half-Year Earnings: Have Analysts Changed Their Mind On The Stock?

Feb 25

New Forecasts: Here's What Analysts Think The Future Holds For Australian Clinical Labs Limited (ASX:ACL)

Dec 22

The Market Lifts Australian Clinical Labs Limited (ASX:ACL) Shares 31% But It Can Do More

Dec 21

The Strong Earnings Posted By Australian Clinical Labs (ASX:ACL) Are A Good Indication Of The Strength Of The Business

Sep 01

Rendimenti per gli azionisti

	ACL	AU Healthcare	AU Mercato
7D	-4.5%	0.09%	1.4%
1Y	34.1%	2.4%	17.7%

Ritorno vs Industria: ACL ha superato il Australian Healthcare che ha restituito 2.4 % nell'ultimo anno.

Rendimento vs Mercato: ACL ha superato il mercato Australian che ha restituito 17.7 % nell'ultimo anno.

Volatilità dei prezzi

Is ACL's price volatile compared to industry and market?
ACL volatility
ACL Average Weekly Movement	5.1%
Healthcare Industry Average Movement	5.1%
Market Average Movement	8.6%
10% most volatile stocks in AU Market	17.3%
10% least volatile stocks in AU Market	3.4%

Prezzo delle azioni stabile: ACL non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 5% ) di ACL è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2020	4,900	Melinda McGrath	www.clinicallabs.com.au

Australian Clinical Labs Limited fornisce servizi di diagnostica patologica in Australia. L'azienda offre una gamma di servizi che comprendono test patologici di routine, test avanzati di genetica molecolare, harmony NIPT e screening del primo trimestre, screening dei portatori genetici, patologia chimica, istopatologia e citopatologia, ematologia, allergia e immunologia, sierologia e microbiologia, test molecolari infettivi, servizi di analisi cardiaca, patologia funzionale, patologia veterinaria e servizi di test commerciali per droghe e alcol. Offre i suoi servizi a ospedali pubblici e privati.

Australian Clinical Labs Limited Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Australian Clinical Labs con la sua capitalizzazione di mercato?
ACL statistiche fondamentali
Capitalizzazione di mercato	AU$686.83m
Guadagni(TTM)	AU$23.93m
Ricavi(TTM)	AU$696.37m

28.5x

Rapporto P/E

1.0x

Rapporto P/S

ACL è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
ACL Conto economico (TTM)
Ricavi	AU$696.37m
Costo del fatturato	AU$442.37m
Profitto lordo	AU$254.00m
Altre spese	AU$230.07m
Guadagni	AU$23.93m

Ultimi guadagni dichiarati

Jun 30, 2024

Prossima data di guadagno

Feb 26, 2025

Utile per azione (EPS)	0.12
Margine lordo	36.48%
Margine di profitto netto	3.44%
Rapporto debito/patrimonio netto	31.0%

Come si è comportato ACL nel lungo periodo?

Vedi performance storica e confronto

Dividendi

3.5%

Rendimento attuale del dividendo

100%

Rapporto di remunerazione

ACL Panoramica delle azioni

Premi

Analisi del rischio

Australian Clinical Labs Limited Concorrenti

ASX:HLA

AU$252.1m

ASX:SLA

AU$177.4m

ASX:AHX

AU$85.8m

ASX:SHL

AU$13.4b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Australian Clinical Labs Limited to Report Fiscal Year 2025 Results on Aug 26, 2025

Investor sentiment improves as stock rises 25%

Why Investors Shouldn't Be Surprised By Australian Clinical Labs Limited's (ASX:ACL) 29% Share Price Surge

Should You Think About Buying Australian Clinical Labs Limited (ASX:ACL) Now?

Final dividend of AU$0.09 announced

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

Australian Clinical Labs Limited to Report Fiscal Year 2025 Results on Aug 26, 2025

Investor sentiment improves as stock rises 25%

Why Investors Shouldn't Be Surprised By Australian Clinical Labs Limited's (ASX:ACL) 29% Share Price Surge

Should You Think About Buying Australian Clinical Labs Limited (ASX:ACL) Now?

Final dividend of AU$0.09 announced

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Australian Clinical Labs Limited Provides Financial Guidance for the Fiscal Year 2025

Australian Clinical Labs Limited to Report Fiscal Year 2024 Results on Aug 29, 2024

Australian Clinical Labs Limited, Annual General Meeting, Oct 25, 2024

We Think Australian Clinical Labs (ASX:ACL) Is Taking Some Risk With Its Debt

Upcoming dividend of AU$0.03 per share

Consensus EPS estimates fall by 20%

First half dividend reduced to AU$0.03

First half 2024 earnings released: EPS: AU$0.025 (vs AU$0.13 in 1H 2023)

Are Investors Undervaluing Australian Clinical Labs Limited (ASX:ACL) By 46%?

Australian Clinical Labs Limited to Report First Half, 2024 Results on Feb 28, 2024

Is It Time To Consider Buying Australian Clinical Labs Limited (ASX:ACL)?

Price target decreased by 7.5% to AU$3.56

Upcoming dividend of AU$0.07 per share at 4.6% yield

Consensus EPS estimates fall by 21%

Australian Clinical Labs Limited Announces Appointment of Christine Bartlett as Non-Executive Director

Australian Clinical Labs Limited Declares Full Year Fully Franked Dividend for the Fiscal Year 2023, Payable on 3 October 2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of AU$0.07 per share at 13% yield

Price target increased by 7.1% to AU$4.03

First half 2023 earnings released: EPS: AU$0.13 (vs AU$0.65 in 1H 2022)

Australian Clinical Labs Limited Announces Dividend for the Six Months Ended December 31, 2022, Payable on April 26, 2023

Investor sentiment improves as stock rises 16%

Price target decreased by 8.5% to AU$3.76

Price target decreased to AU$4.27

High number of new and inexperienced directors

Price target decreased to AU$4.62

Independent Non-Executive Director recently sold AU$71k worth of stock

Australian Clinical Labs Limited Announces Resignation of Dr. Michael Stanford as Non-Executive Director

Australian Clinical Labs Limited, Annual General Meeting, Oct 25, 2023

Independent Non-Executive Director recently sold AU$140k worth of stock

Upcoming dividend of AU$0.41 per share

Here's Why We Think Australian Clinical Labs (ASX:ACL) Might Deserve Your Attention Today

Full year 2022 earnings: EPS misses analyst expectations

Price target decreased to AU$5.30

Australian Clinical Labs Limited Declares Dividend for the Period of Six Months Ended 30 June 2022

Investor sentiment deteriorated over the past week

CEO & Executive Director recently bought AU$335k worth of stock

High number of new and inexperienced directors

First half 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Australian Clinical Labs Limited Declares Ordinary Dividend for the Period of Six Months December 31, 2021, Payable April 21, 2022

Australian Clinical Labs Limited (ASX:ACL) Just Reported Half-Year Earnings: Have Analysts Changed Their Mind On The Stock?

Australian Clinical Labs Limited Revises Earnings Guidance for the First Half 2022

New Forecasts: Here's What Analysts Think The Future Holds For Australian Clinical Labs Limited (ASX:ACL)

The Market Lifts Australian Clinical Labs Limited (ASX:ACL) Shares 31% But It Can Do More

Investor sentiment improved over the past week

Consensus EPS estimates increase by 46%

Australian Clinical Labs Limited (ASX:ACL) completed the acquisition of Medlab Pathology Pty Ltd.

Independent Non-Executive Director recently bought AU$99k worth of stock

The Strong Earnings Posted By Australian Clinical Labs (ASX:ACL) Are A Good Indication Of The Strength Of The Business

Full year 2021 earnings released: EPS AU$0.40 (vs AU$0.28 in FY 2020)

Australian Clinical Labs Limited Provides Earnings Guidance for the Fiscal Year of 2021

Australian Clinical Labs Limited has completed an IPO in the amount of AUD 408.559209 million.

Rendimenti per gli azionisti